Cambridge Advisors Inc. Sells 287 Shares of Johnson & Johnson $JNJ

Cambridge Advisors Inc. lowered its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.3% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 12,117 shares of the company’s stock after selling 287 shares during the period. Cambridge Advisors Inc.’s holdings in Johnson & Johnson were worth $1,851,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Elios Financial Group Inc. grew its holdings in Johnson & Johnson by 1.5% in the 1st quarter. Elios Financial Group Inc. now owns 4,496 shares of the company’s stock worth $746,000 after acquiring an additional 66 shares during the last quarter. Atlantic Family Wealth LLC grew its holdings in Johnson & Johnson by 4.4% in the 1st quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company’s stock worth $266,000 after acquiring an additional 67 shares during the last quarter. MBA Advisors LLC grew its holdings in Johnson & Johnson by 1.2% in the 1st quarter. MBA Advisors LLC now owns 5,553 shares of the company’s stock worth $921,000 after acquiring an additional 68 shares during the last quarter. Sovereign Financial Group Inc. grew its holdings in Johnson & Johnson by 1.8% in the 1st quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company’s stock worth $651,000 after acquiring an additional 69 shares during the last quarter. Finally, Nabity Jensen Investment Management Inc grew its holdings in Johnson & Johnson by 1.5% in the 1st quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company’s stock worth $767,000 after acquiring an additional 69 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 1.1%

Shares of NYSE JNJ opened at $179.69 on Friday. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $181.16. The stock has a market cap of $432.75 billion, a P/E ratio of 19.22, a price-to-earnings-growth ratio of 2.26 and a beta of 0.40. The firm has a 50-day moving average of $174.41 and a 200 day moving average of $162.06. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $23.74 billion during the quarter, compared to analysts’ expectations of $22.85 billion. During the same period last year, the company posted $2.82 EPS. Johnson & Johnson’s revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, sell-side analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio (DPR) is 55.61%.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Wall Street Zen raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Saturday, September 13th. Barclays lifted their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a research note on Thursday, July 17th. Guggenheim raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their target price for the company from $167.00 to $206.00 in a research note on Tuesday. Piper Sandler reaffirmed an “overweight” rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Finally, Morgan Stanley lifted their target price on shares of Johnson & Johnson from $171.00 to $176.00 and gave the company an “equal weight” rating in a research note on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $181.40.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.